East China Medicine's Subsidiary Daoer Bio Receives IND Approval for DR30206, a First-in-Class Trispecific Antibody Targeting PD-L1/VEGF/TGF-β, for Advanced Gastrointestinal Cancers

On April 7, Huadong Medicine Co., Ltd. announced that itsThe application submitted by the holding subsidiary Doer BiologicsClinical Trial Application for Injectable DR30206 ApprovedCombined with standardized chemotherapy, intended forPatients with advanced or metastatic gastrointestinal tumors。

DR30206 is a Class 1 therapeutic biologic independently developed by Doer Biologics with global intellectual property rights.Antibody fusion protein targeting PD-L1, VEGF, and TGF-β; By blocking the PD-1/PD-L1 signaling pathway, the proliferation of exhausted CD8+T cells is restored; by specifically binding to free VEGF and TGF-β, the formation of tumor neovascularization is reduced while immunosuppression is relieved, thereby achieving the purpose of treating tumors.

DR30206 was first applied for clinical trials in China in April 2023 and was first approved for clinical trials in June of the same year, with indications forAdvanced Solid Tumors, First Clinical Disclosure in November 2023.

The results of completed non-clinical studies and ongoing Phase I clinical trials show that DR30206 has a clear mechanism of action.Inhibit Tumor GrowthThe effect,With good safety, which can support the clinical trial of DR30206 in combination with standardized chemotherapy in patients with advanced or metastatic gastrointestinal tumors.

Insight database shows that currently, there are only 3PD-L1, VEGF, and TGF-β Triple-Target Targeted Drug Under Research(Active status only), respectively fromHuadong Medicine, Primus BioAndQiyue Biologics, all produced in China.

Screenshot Source：Insight Database

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If you have any needs, please consult and contact正规医疗机构.

Editor：ccai

PR Article Coordination: WeChat insightxb

SubmissionWeChat: insightxb; Email: insight@dxy.cn

Diversified functions, traceable data……

Insight Database Web Version Awaits Your Experience

Click to read the original text,ImmediatelyUnlock！